Summary of Argenx Update / Briefing on September 16, 2025 Company Overview - **Company**: Argenx (NasdaqGS: ARGX) - **Focus**: Development of argenx 119, a Musk agonist targeting neuromuscular junction diseases Key Points and Arguments Industry and Product Development - Argenx is spotlighting argenx 119, which is moving into a registrational study for Congenital Myasthenic Syndromes (CMS) after a GO decision in June 2025 [2][4] - The company aims to be involved in 50,000 patients across all medicines by 2030, with 10 labeled indications and 5 new late-stage studies [4] - Argenx 119 is part of a broader vision to bring transformational biology to patients, with a focus on foundational components of the immune system [5][6] Clinical Trials and Data - Argenx 119 is currently in phase 3 trials for CMS, Amyotrophic Lateral Sclerosis (ALS), and Spinal Muscular Atrophy (SMA) [5][8] - The company has a data-rich approach to developing treatments for CMS, utilizing digital sensors to gather real-world data from patients [10][68] - A phase 1B study enrolled 16 patients with CMS, showing a favorable safety profile and proof of biology, leading to plans for a registrational study [72][80] Mechanism of Action - Argenx 119 targets muscle-specific kinase (MuSK), which is crucial for the formation and maintenance of neuromuscular junctions [17][20] - The drug promotes MuSK activation, leading to clustering of acetylcholine receptors, which is essential for muscle contraction [17][20] - The mechanism is particularly relevant for patients with congenital myasthenic syndromes caused by mutations affecting neuromuscular junction proteins [21][22] Collaboration and Innovation - The development of argenx 119 involved collaboration with key opinion leaders and researchers, emphasizing the importance of partnerships in advancing drug development [6][19] - The Immunology Innovation Program (IIP) has been instrumental in sourcing novel biology and driving transformational outcomes [6][7] Patient Impact and Testimonials - The briefing included a patient testimonial highlighting the severe impact of CMS and the lack of effective treatments, underscoring the urgency of developing argenx 119 [63][66] - The company aims to empower patients and improve their quality of life through innovative treatments [68][81] Future Directions - Argenx is exploring additional indications for argenx 119 beyond CMS, including ALS, where there are currently no effective treatments available [58][59] - The company plans to continue leveraging data from ongoing studies to refine treatment approaches and enhance patient outcomes [70][80] Additional Important Content - The neuromuscular junction's biology and the role of various proteins, including Agrin, LRP4, and DOK7, were discussed, emphasizing the complexity of neuromuscular diseases [12][13][16] - The collaboration between academic researchers and Argenx has led to significant advancements in understanding neuromuscular junction biology and developing targeted therapies [44][46] This summary encapsulates the key points from the Argenx briefing, focusing on the company's strategic direction, product development, clinical trial outcomes, and the broader implications for patients suffering from neuromuscular diseases.

Company Overview - argenx is a global immunology company focused on improving the lives of individuals suffering from severe autoimmune diseases [3] - The company is known for developing and commercializing the first approved neonatal Fc receptor (FcRn) blocker, with ongoing evaluations for its potential in various serious autoimmune diseases [3] Upcoming Events - argenx will host a conference call and audio webcast on July 31, 2025, at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half-year 2025 financial results and provide a second-quarter business update [1] - The live call can be accessed via the Investors section of the argenx website, with a replay available for approximately one year [2] Contact Information - Media inquiries can be directed to Ben Petok at bpetok@argenx.com [4] - Investor relations can be contacted through Alexandra Roy at aroy@argenx.com [4]

Core Points - Argenx SE held its Annual General Meeting on May 27, 2025, with 91.1% of the share capital represented [1] - All agenda items received the required majority except for the remuneration policy, which received a 73.0% majority against a required 75% [2] - The company's 2024 remuneration report received a 76.7% majority in favor [4] - The annual report and accounts for the financial year ending December 31, 2024, were approved with a 99.9% majority [4] - Anthony Rosenberg was re-appointed as a non-executive director for a two-year term with a 93.6% majority [4] - The Board of Directors was authorized to issue shares and grant rights to subscribe for shares for up to 10% of the outstanding share capital for 18 months, with a 99.4% majority [4] Company Overview - Argenx is a global immunology company focused on improving the lives of individuals with severe autoimmune diseases [3] - The company collaborates with leading academic researchers through its Immunology Innovation Program to develop novel antibody-based medicines [3] - Argenx has developed the first approved neonatal Fc receptor (FcRn) blocker and is exploring its potential in various serious autoimmune diseases [3]